HK Stock Market Move | HUA MEDICINE-B(02552) rose over 3% as the second-generation GKA American MAD Ib trial succeeded in dosing. The company plans to seek future cooperation partners.

HUA MEDICINE-B (02552) rose more than 3%, reaching 3.17% at the time of publication, at 3.25 Hong Kong dollars, with a trading volume of 3.303 million Hong Kong dollars. On the news front, on December 9th, HUA MEDICINE-B announced that the first patient in the United States has successfully received the second-generation glucokinase activator (GKA) HMS1005 (formerly known as HM-002-1005) in a multiple ascending dose (MAD) Phase Ib trial. The study is a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetic characteristics, and pharmacological effects of multiple ascending doses of HMS1005 in American type 2 diabetes (T2D) subjects. In this study, PD biomarkers (including blood glucose, insulin, C peptide, GLP-1, and glucagon) will be evaluated in fasting and postprandial states, and blood glucose fluctuations will be monitored by continuous glucose monitoring devices (CGM) to further explore the mechanism of action and efficacy of HMS1005. HMS1005 is a novel molecular entity with improved physicochemical properties designed as a sustained-release formulation for once-daily dosing, providing more convenience to patients and increasing the duration of the drug in the intestine to enhance restoration of inadequate GLP-1 secretion in patients. Previously, the company successfully completed and announced the results of HMS1005 single ascending dose studies in the United States, confirming the feasibility of once-daily oral treatment for T2D and obese patients. In addition, after the successful completion of the MAD Phase Ib study, the company plans to seek partners to develop HMS1005 for the global market.